The U.K.’s National Institute for Health and Care Excellence (NICE) earlier this week rejected coverage of Johnson & Johnson’s heavily-criticized depression nasal spray, Spravato, FiercePharma reports.
According to the report, NICE backed away from the drug due to concerns about the drug’s price and lack of comparative data.
“Introduction of esketamine into clinical practice in the [National Health Service] will be complex because the structure and delivery of services would need to be changed,” NICE’s Meindert Boysen said in a statement. “Estimates of the costs of providing the clinical service for esketamine were highly uncertain, as are the costs of repeated courses of the drug.”
To read the full report on FiercePharma, click here.